Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Custom stents aim to cut deaths from tricky aortic aneurysms

NCT ID NCT02043691

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests three custom-made stents for people with complex aortic aneurysms that standard devices can't treat. The goal is to see if these stents reduce deaths, lung problems, and hospital stays. About 410 adults with certain types of aortic aneurysms will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 410 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2014

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Juxtarenal, suprarenal, and thoracoabdominal aortic pathology as follows in hemodynamically stable patients: 1. Intact or contained ruptured aortic or aortoiliac aneurysms (atherosclerotic/degenerative or saccular) involving or in close approximation to the visceral segment of the aorta. 1. Diameter \> 5.5 cm if asymptomatic, or 5.0 cm with enlargement of \> 0.5 cm in 6 months. 2. History of growth \> 0.5 cm per year 3. Any size if ruptured or symptomatic 2. Penetrating aortic ulcer (PAU) 1. \> 2.0 cm in depth 2. Any size if contained ruptured or symptomatic 3. Subacute (\>14 days) or chronic (\>20 days) aortic dissection with aneurysmal degeneration with at least one of the following: 1. Total aortic diameter \> 5.5 cm if asymptomatic 2. Total aortic diameter \> 4.5 cm if symptomatic 3. Total aortic diameter \> 5.0 cm and history of growth \> 0.5 cm in 6 months * Aortic Arch pathology: 1. Aneurysm, Ascending thoracic aortic pseudoaneurysm, Type A thoracic aortic dissection, Retrograde type A thoracic aortic dissection between the Sinus of Valsalva and the innominate artery orifice (without involvement of the Aortic Valve), or Ascending penetrating aortic ulcer with and without intramural hematoma 2. Suitable iliac artery and brachial artery access 3. Absence of severe landing zone (\> 90 degree) angulation that would preclude necessary device delivery/seal/fixation. 4. Suitable iliac artery access to accommodate device delivery system. 5. Target arteries for arch branches: 1. \< 24 mm diameter 2. Adequate landing zone length to obtain proximal and distal seal. 3. Free from dissection precluding adequate seal in distal landing zone of branch stent and severe tortuosity/thrombus/calcification. * Aortic Arch Aneurysm 1. Proximal aortic fixation zone: 1. Native aorta or surgical graft 2. Diameter: 20 - 42 mm 2. Proximal neck length \> 20 mm 3. Must occur distal to coronary arteries and any coronary artery bypass grafts that are considered patent and necessary for proper cardiac perfusion. 4. Distal aortic fixation zone: 1. Native aorta or surgical graft 2. Diameter: 20 - 44 mm 5. Distal neck length \> 20 mm. However, if dissection, distal graft may land in dissected aorta. 6. Supra-aortic trunk (brachiocephalic) vessels (Any combination of arteries may be used for repair) A. Innominate artery 1. Native vessel or surgical graft 2. Diameter: 8 - 22 mm 3. Length of sealing zone \> 10 mm 4. Acceptable tortuosity B. Left (or right) common carotid artery <!-- --> 1. Native vessel or surgical graft 2. Diameter 5 - 20 mm 3. Length of sealing zone \> 10 mm C. Left (or right) subclavian artery <!-- --> 1. Native vessel or surgical graft 2. Diameter 5 - 20 mm 3. Length of sealing zone \> 10 mm * Aortic Dissection 1. Access into the true lumen from the groin and at least one supra-aortic trunk vessel. 2. Seal zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stent-graft would be anticipated to seal off the dissection lumen. 3. Seal zone in the target supra-aortic trunk vessels that is distal to the dissection, anticipated to seal off the dissection lumen or surgically created. 4. True lumen size large enough to deploy the device and still gain access into the target branch. General Exclusion Criteria: * Less than 18 years of age * Life expectancy less than 12 months based on the surgeon's assessment * Pregnant or breastfeeding or planning on becoming pregnant within 60 months * Inability or refusal to give informed consent * Unwilling or unable to comply with the follow-up schedule * Less than 30 days beyond primary endpoint for other investigative drug or device study Medical Exclusion Criteria: * Known allergy to the device components (i.e. stainless steel, polyester, solder, gold, or nitinol) * History of anaphylactic reaction to contrast material that cannot be adequately premedicated * Systemic or local infection that may increase the risk of endovascular graft infection. * Baseline eGFR \< 30 mL/min (calculated by the Modification of Diet in Renal Disease formula) and not on hemo- or peritoneal dialysis. If the patient is currently on dialysis, or is currently planning on initiating dialysis, then they may undergo repair. * Body habitus that would inhibit X-ray visualization of the aorta. * Major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤ 30 days of the endovascular repair. * Unstable angina, defined as a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina. * Irreversible coagulopathy Anatomical Exclusion Criteria: * Aortic transection due to acute trauma. * Infectious ("mycotic") etiology of the aortic disease. * Significant occlusive disease or tortuosity precluding delivery of the device components. * Juxtarenal, Suprarenal, and Thoracoabdominal: * Proximal Landing zone \< 20 mm in length. The proximal landing zone can be within zones 2 through 8, with least 20 mm of proximal seal and fixation in aorta or Dacron. * Proximal neck, defined as the thoracic aorta distal to the native left carotid artery, measured outer wall to outer wall on a sectional image (CT) \> 41 mm in diameter or \< 18 mm in diameter * Distal landing zone \< 20 mm in length if the landing zone is in the aorta, or \< 20 mm if the landing zone is in the iliac arteries or in Dacron (in the event the patient has had a previous or concomitant aortic or aorto-iliac reconstruction). * Untreatable branch vessel stenosis. * Anatomy that would not allow maintenance of at least one patent hypogastric artery. * Signs that the inferior mesenteric artery (IMA) is indispensable (i.e. angiographic visualization or a large IMA, filling of superior mesenteric artery (SMA) via collaterals, stenosis of celiac or SMA or oblique views) and the indispensable IMA is not amenable to treatment with a graft branch or fenestration. * Branching, duplication, aneurysm or untreatable stenosis of the celiac, SMA or renal arteries that would preclude implantation of the investigational devices. * Aortic arch: * Proximal neck \> 44 mm or \< 28 mm in diameter * Inadequate landing zone to allow adequate distal seal of exclusion of false lumen perfusion in dissection. * Untreatable branch vessel stenosis. * Significant occlusive disease, tortuosity, or calcification that would prevent endovascular access. * Patients qualifying for an industry-sponsored study allowing for a similar repair will be enrolled in the industry-sponsored study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic arch aneurysm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal aortic aneurysm Aneurysm Aneurysm, Aortic Arch aortic aneurysm Aortic Aneurysm, Thoracoabdominal Aortic Dissection Penetrating Atherosclerotic Ulcer thoracic aortic aneurysm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.